ABT's diversified diagnostics/nutrition/medtech segments drive multi-pronged growth prospects, as the management targets a +7% organic growth rate. The recent EXAS acquisition introduces balance sheet/bottom-line risks, albeit with the new Cancer Diagnostic segment delivering double-digit growth rates. The prior meltdown unlocks the cheap valuations, the richer dividend yields, and the excellent upside potential to my bull-case LTPT of $139.
Abbott's raised 2026 earnings outlook and four growth drivers point to a faster second half across nutrition, devices, diagnostics and diabetes care.
Abbott Laboratories (ABT) Q2 2026 Earnings Call Transcript
| Pharmaceuticals Industry | Healthcare Sector | Robert Ford CEO | XMUN Exchange | US0028241000 ISIN |
| US Country | 114,000 Employees | 15 Jul 2026 Last Dividend | 2 Jan 2013 Last Split | 13 Jan 1978 IPO Date |
Abbott Laboratories is a global healthcare company that engages in the discovery, development, manufacturing, and sale of a wide range of health care products. With its foundation laid in 1888, and headquartered in North Chicago, Illinois, the company has established a significant presence worldwide. Abbott operates across four main sectors: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices, catering to a diverse range of healthcare needs from generic pharmaceuticals to advanced medical devices.
Abbott Laboratories offers a comprehensive portfolio of products and services across various healthcare domains: